AIT-082 is a potentially new therapeutic agent for Alzheimer's Disease. Preclinical experiments indicate that AIT-082 has memory enhancing and neurotrophic properties. This protocol describes a Phase I development program for AIT-082 in Alzheimer's disease. Two clinical trials are planned. The first clinical trial will evaluate single dose safety, tolerance and pharmacokinetics in elderly, non-demented, healthy volunteers. Eight subjects will be recruited. Each subject will receive a single oral dose of AIT-082 on a weekly basis for five weeks. Subjects will be observed for adverse reactions throughout the study. Subjects will be permitted to advance to the next higher dose only when the last preceding dose is deemed safe and well tolerated. Blood and urine will be collected to determine pharmacokinetic parameters. A second trial will evaluate safety and tolerance of multiple dosing in patients with Alzheimer's disease. Twenty four patients will receive medication three times daily for one week. Patients will be randomized to receive one of three doses of AIT-082 or placebo. The frequency of physical exam abnormalities and adverse events will be tabulated for each dose. Selected efficacy measures will be incorporated for possible evidence of therapeutic benefit. These include the Cognitive portion of the Alzheimer's Disease Assessment Scale, the ADCS-Clinical Global Impression of Change, the Mini-Mental State Examination and the ADCS- Activities of Daily Living scale.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG010483-09
Application #
6218744
Study Section
Project Start
1999-09-17
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Rockenstein, Edward; Ostroff, Gary; Dikengil, Fusun et al. (2018) Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci 38:1000-1014
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2017) Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry 25:1150-1159

Showing the most recent 10 out of 294 publications